Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention.
Fusar-Poli P, Salazar de Pablo G, Correll CU, Meyer-Lindenberg A, Millan MJ, Borgwardt S, Galderisi S, Bechdolf A, Pfennig A, Kessing LV, van Amelsvoort T, Nieman DH, Domschke K, Krebs MO, Koutsouleris N, McGuire P, Do KQ, Arango C.
JAMA Psychiatry. 2020 Jul 1;77(7):755-765. doi: 10.1001/jamapsychiatry.2019.4779.
Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Lowe H, Toyang N, Steele B, Grant J, Ali A, Gordon L, Ngwa W.
Molecules. 2022 Apr 14;27(8):2520. doi: 10.3390/molecules27082520.
Risk and protective factors for mental disorders beyond genetics: an evidence-based atlas.
Arango C, Dragioti E, Solmi M, Cortese S, Domschke K, Murray RM, Jones PB, Uher R, Carvalho AF, Reichenberg A, Shin JI, Andreassen OA, Correll CU, Fusar-Poli P.
World Psychiatry. 2021 Oct;20(3):417-436. doi: 10.1002/wps.20894.
Associations of cannabis use, tobacco use, and incident anxiety, mood, and psychotic disorders: a systematic review and meta-analysis.
Burke C, Freeman TP, Sallis H, Wootton RE, Burnley A, Lange J, Lees R, Sawyer K, Taylor GMJ.
Psychol Med. 2024 Dec 2;54(15):1-15. doi: 10.1017/S0033291724002587. Online ahead of print.
Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).
Sass MR, Danielsen AA, Köhler-Forsberg O, Storgaard H, Knop FK, Nielsen MØ, Sjödin AM, Mors O, Correll CU, Ekstrøm C, Vinberg M, Nielsen J, Vilsbøll T, Fink-Jensen A.
BMJ Open. 2023 Jan 31;13(1):e068652. doi: 10.1136/bmjopen-2022-068652.
Mediating Effect of Perceived Stress on the Association between Physical Activity and Sleep Quality among Chinese College Students.
Zhai X, Wu N, Koriyama S, Wang C, Shi M, Huang T, Wang K, Sawada SS, Fan X.
Int J Environ Res Public Health. 2021 Jan 2;18(1):289. doi: 10.3390/ijerph18010289.
Psychedelics as a potential treatment for tobacco use disorder: a systematic review.
Spoelstra SK, Schoevers RA, Venema SD, Knegtering H.
Discov Ment Health. 2024 Sep 17;4(1):37. doi: 10.1007/s44192-024-00095-0.
History of tobacco smoking and alcohol use can predict the effectiveness of electroconvulsive therapy in individuals with schizophrenia: A multicenter clinical trial.
Xie H, Ma R, Yu M, Wang T, Chen J, Liang J, Ren J, Tan Q, Feng S, Wang P, Zhang H, Peng W, Liu K, Xiang B.
J Psychiatr Res. 2024 Dec;180:1-7. doi: 10.1016/j.jpsychires.2024.09.045. Epub 2024 Sep 30.
Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis.
González-Blanco L, García-Portilla MP, Gutiérrez M, Mezquida G, Cuesta MJ, Urbiola E, Amoretti S, Barcones F, González-Pinto A, Pina-Camacho L, Corripio I, Vieta E, Baeza I, Toll A, Sáiz PA, Bobes J, Bernardo M; PEPs Group.
Schizophr Res. 2021 Oct;236:19-28. doi: 10.1016/j.schres.2021.07.017. Epub 2021 Aug 5.
Cannabis and tobacco use in bipolar disorder: Associations with early onset, psychotic symptoms, and relapse risk (2015-2019).
Olivier L, Andreu H, de Juan O, Ochandiano I, Salmerón S, Fernández-Plaza T, Colomer L, Vieta E, Giménez-Palomo A, Pacchiarotti I.
J Affect Disord. 2025 Aug 1;382:30-38. doi: 10.1016/j.jad.2025.04.026. Epub 2025 Apr 11.
